EFM
E Fund Management Portfolio holdings
AUM
$2.1B
1-Year Return
23.31%
This Quarter Return
+1.57%
1 Year Return
+23.31%
3 Year Return
+155.42%
5 Year Return
–
10 Year Return
–
AUM
$1.61B
AUM Growth
+$36.4M
(+2.3%)
Cap. Flow
+$105M
Cap. Flow
% of AUM
6.47%
Top 10 Holdings %
Top 10 Hldgs %
61.46%
Holding
387
New
81
Increased
131
Reduced
147
Closed
19
Top Buys
| 1 |
ASE Group
ASX
|
$25.3M |
| 2 |
Microsoft
MSFT
|
$12.9M |
| 3 |
NVIDIA
NVDA
|
$11.9M |
| 4 |
Apple
AAPL
|
$9.18M |
| 5 |
Amazon
AMZN
|
$7.47M |
Top Sells
| 1 |
Sea Limited
SE
|
$24.3M |
| 2 |
Advanced Micro Devices
AMD
|
$16.8M |
| 3 |
TSMC
TSM
|
$8M |
| 4 |
Weibo
WB
|
$2.43M |
| 5 |
Pinduoduo
PDD
|
$2.4M |
Sector Composition
| 1 | Consumer Discretionary | 40.2% |
| 2 | Technology | 29.79% |
| 3 | Communication Services | 9.9% |
| 4 | Healthcare | 5.71% |
| 5 | Real Estate | 4.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
201
Rocket Pharmaceuticals
RCKT
$349M
| $419K | 0.03% |
15,549
+4,352
| +39% | +$117K |
|
|
SWTX
202
DELISTED
SpringWorks Therapeutics
SWTX
| $418K | 0.03% |
8,486
+734
| +9% | +$36.1K |
|
203
IDEAYA Biosciences
IDYA
$2.26B
| $417K | 0.03% |
9,512
-873
| -8% | -$38.3K |
|
204
Arcellx
ACLX
$4B
| $416K | 0.03% |
5,986
-26
| -0.4% | -$1.81K |
|
205
Amicus Therapeutics
FOLD
$2.47B
| $415K | 0.03% |
35,232
-7,316
| -17% | -$86.2K |
|
206
Apellis Pharmaceuticals
APLS
$3.62B
| $413K | 0.03% |
7,032
-625
| -8% | -$36.7K |
|
207
Gartner
IT
$17.9B
| $411K | 0.03% |
862
-15
| -2% | -$7.15K |
|
208
Super Micro Computer
SMCI
$24.2B
| $410K | 0.03% |
+4,060
| New | +$410K |
|
209
United Therapeutics
UTHR
$17.2B
| $410K | 0.03% |
1,783
-205
| -10% | -$47.1K |
|
210
Dynavax Technologies
DVAX
$1.17B
| $409K | 0.03% |
32,980
+3,964
| +14% | +$49.2K |
|
211
Iovance Biotherapeutics
IOVA
$796M
| $409K | 0.03% |
27,602
-39,136
| -59% | -$580K |
|
212
Biohaven
BHVN
$1.7B
| $409K | 0.03% |
7,476
-7,052
| -49% | -$386K |
|
213
Vaxcyte
PCVX
$4.17B
| $407K | 0.03% |
5,962
-2,514
| -30% | -$172K |
|
214
PVH
PVH
$4.29B
| $406K | 0.03% |
+2,888
| New | +$406K |
|
215
PTC Therapeutics
PTCT
$4.61B
| $405K | 0.03% |
13,908
-4,280
| -24% | -$125K |
|
216
Keurig Dr Pepper
KDP
$39.7B
| $403K | 0.03% |
13,145
-249
| -2% | -$7.64K |
|
217
Alkermes
ALKS
$4.77B
| $401K | 0.02% |
14,816
-3,757
| -20% | -$102K |
|
218
Kymera Therapeutics
KYMR
$3.02B
| $401K | 0.02% |
+9,965
| New | +$401K |
|
219
Ultragenyx Pharmaceutical
RARE
$3.01B
| $400K | 0.02% |
8,577
-3,294
| -28% | -$154K |
|
220
Intellia Therapeutics
NTLA
$1.25B
| $398K | 0.02% |
14,460
-2,091
| -13% | -$57.5K |
|
221
Diamondback Energy
FANG
$41.3B
| $398K | 0.02% |
2,006
+223
| +13% | +$44.2K |
|
222
Twist Bioscience
TWST
$1.55B
| $396K | 0.02% |
11,535
-748
| -6% | -$25.7K |
|
223
Illumina
ILMN
$15.5B
| $395K | 0.02% |
2,956
-17
| -0.6% | -$2.27K |
|
224
TG Therapeutics
TGTX
$5.06B
| $393K | 0.02% |
25,826
-4,727
| -15% | -$71.9K |
|
225
Charter Communications
CHTR
$35.4B
| $393K | 0.02% |
1,351
-58
| -4% | -$16.9K |
|